Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » CuraGen, Gemini in Target Discovery Collaboration

CuraGen, Gemini in Target Discovery Collaboration

Apr 07, 2000
Premium

C

AMBRIDGE, UK--Gemini Genomics, formerly Gemini Holdings, announced that it has entered into a two-year drug target identification collaboration with CuraGen to accelerate drug discovery. CuraGen and Gemini scientists will work together to associate CuraGen's thousands of single-nucleotide polymorphisms with disease traits derived from Gemini's database of clinical populations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Germany to Increase Viral Sequencing

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

Green Access at Science

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

Getting Used to It

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

Science Papers Examine Chronic Kidney Disease GWAS, Pneumonia Microbiome

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

What's Popular?

In Informatics

  1. PGDx, Qiagen Partner on Clinical Decision Support for Molecular Cancer Testing

  2. Nvidia to Embed High-Performance Compute System Into Oxford Nanopore PromethIon Sequencers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.